Home Blog

0 6

Patent Number: 9,090,909

Grant date: December 31, 1969
Priority date: June 14, 2002
Estimated expiration date: June 14, 2022
Inventor(s): Ban; Hiroshi (Tsukuba, JP), Ueda; Yasuji (Tsukuba, JP), Fusaki; Noemi (Tsukuba, JP), Saeki; Koichi (Tsukuba, JP), Hasegawa; Mamoru (Tsukuba, JP)
Assignee(s): DNAVEC CORPORATION (Ibaraki, JP)
External link: USPTO website

Abstract:

The present invention provides Sendai virus vectors in which genes that encode reprograming factors for inducing pluripotent stem cells are incorporated in a specific order, compositions comprising these vectors for gene delivery to be used in the induction of pluripotent stem cells, and uses thereof. Incorporation of the KLF gene, OCT gene, and SOX gene in a specific order into a single Sendai virus vector successfully and significantly increased the efficiency of pluripotent stem cell induction. Loading multiple reprogramming factors into a single vector can further increase the induction efficiency of pluripotent stem cells while reducing the number of necessary vectors.

0 6

Patent Number: 9,090,908

Grant date: December 31, 1969
Priority date: June 14, 2002
Estimated expiration date: June 14, 2022
Inventor(s): Trono; Didier (Collonge, CH), Cosset; Francois-Loic (Lyons, FR), Sandrin; Virginie (Lyons, FR)
Assignee(s): INSTITUT NATIONAL DE LA RECHERCHE MEDICALE (INSERM) (Paris, FR) INSTITUT CLAYTON DE LA RECHERCHE (Geneva, CH)
External link: USPTO website

Abstract:

A method is provided for producing a recombinant pseudotyped viral vector particle wherein a cell is transfecting with (i) at least one vector construct; (ii) at least one packaging construct; and (iii) an expression construct encoding a chimeric glycoprotein encoded by a nucleic acid comprising the sequence of SEQ ID NO: 1 to yield a producer cell, followed by culturing the producer cell in a medium; and separating the producer cell from the medium to recover the recombinant viral vector particle from the medium. Vectors obtained in this manner have significantly higher titers than vectors coated with the parental non-chimeric glycoprotein.

0 6

Patent Number: 9,090,878

Grant date: December 31, 1969
Priority date: June 14, 2002
Estimated expiration date: June 14, 2022
Inventor(s): Sancho-Bru; Pau (Barcelona, ES), Verfaillie; Catherine M. (Leuven, BE)
Assignee(s): Katholieke Universiteit Leuven (Leuven, BE)
External link: USPTO website

Abstract:

The invention is directed to methods for culturing cells so that the cells are induced to differentiate into cells that express a hepatic stellate phenotype and cells that express a hepatic sinusoidal endothelial phenotype. The invention is also directed to cells produced by the methods of the invention. The cells are useful, among other things, for treatment of liver deficiency, liver metabolism studies, and liver toxicity studies.

0 6

Patent Number: 9,090,874

Grant date: December 31, 1969
Priority date: June 14, 2002
Estimated expiration date: June 14, 2022
Inventor(s): Roisen; Fred J. (Prospect, KY), Lu; Chengliang (Louisville, KY), Wang; Meng (Louisville, KY), Qiu; Mengsheng (Louisville, KY)
Assignee(s): University of Louisville Research Foundation, Inc. (Louisville, KY)
External link: USPTO website

Abstract:

The presently disclosed subject matter provides recombinant dopaminergic neurons and/or recombinant progenitors thereof that include one or more transgenes encoding a nurr-1 polypeptide, a pitx3 polypeptide, an Imxi a polypeptide, a biologically active fragment thereof, a biologically active derivative thereof, and/or any combination thereof. Also provided are methods for producing a recombinant dopaminergic neuron or recombinant progenitor thereof, methods for producing lineage primed cells, methods for ameliorating at least one symptom associated with a neurological disorder, methods for transplantation, methods for inducing growth, repair, ancllor regeneration of a neuron, for delivering a cytokine or a growth factor to the central nervous system, methods for providing a dopaminergic neuron function, and cell cultures that include recombinant olfactory epithelial-derived stem cells and/or a differentiated derivatives thereof.

0 6

Patent Number: 9,090,866

Grant date: December 31, 1969
Priority date: June 14, 2002
Estimated expiration date: June 14, 2022
Inventor(s): Gazda; Lawrence (Xenia, OH), Laramore; Melissa (Xenia, OH), Hamilton; Timothy (Xenia, OH), Smith; Barry (New York, NY)
Assignee(s): THE ROGOSIN INSTITUTE (New York, NY)
External link: USPTO website

Abstract:

The invention relates to an improved method for making agarose coated, agarose beads which contain cells. The method which is preferably automated, involves placing manufactured beads in a sample of mineral oil at a temperature gradient, such that the temperature drops as the bead moves through the oil. Preferably, a “trumpet tool” and a “straw tool” are employed in the method.

0 7

Patent Number: 9,090,713

Grant date: December 31, 1969
Priority date: June 14, 2002
Estimated expiration date: June 14, 2022
Inventor(s): Czaja; Wojciech (West Chester, PA), Kyryliouk; Dmytro D. (Philadelphia, PA)
Assignee(s): DePuy Synthes Products, Inc. (Raynham, MA)
External link: USPTO website

Abstract:

The present disclosure describes an implant for tissue replacement or augmentation including a resorbable non-pyrogenic porous body of irradiated oxidized cellulose, formed from a precurosr reactive mixture of irradiated cellulose and an oxidizing agent, where the body forms a heterogeneous three-dimensional fibrillar network. Also disclosed is a method for producing a body of oxidized cellulose including irradiating a body of cellulose to form an irradiated body of cellulose, and reacting the irradiated body of cellulose with an oxidizing agent to form a non-pyrogenic porous and resorbable body of oxidized cellulose.

0 7

Patent Number: 9,090,704

Grant date: December 31, 1969
Priority date: June 14, 2002
Estimated expiration date: June 14, 2022
Inventor(s): Rosa; Robert (Holland, TX), Roddy; Gavin W. (Temple, TX), Prockop; Darwin J. (Philadelphia, PA)
Assignee(s): Scott & White Healthcare (Temple, TX) The Texas A&M University System (College Station, TX)
External link: USPTO website

Abstract:

The present invention encompasses methods, compositions, and devices for treating an ocular disease, disorder or condition in a mammal. The invention includes polypeptides that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties, and their application in the treatment of eye disease, particularly diseases of the retina. In particular aspects, the invention includes administration of a therapeutic polypeptide such as a stanniocalcin family member protein for the treatment of an eye disease. Also included are fusion proteins and cells stimulated or modified to express the therapeutic polypeptides as set forth herein.

0 6

Patent Number: 9,090,683

Grant date: December 31, 1969
Priority date: June 14, 2002
Estimated expiration date: June 14, 2022
Inventor(s): Stull; Robert A. (Alameda, CA), Saunders; Laura (San Francisco, CA), Dylla; Scott J. (Emerald Hills, CA), Foord; Orit (Foster City, CA), Liu; David (San Francisco, CA), Torgov; Michael (San Francisco, CA), Shao; Hui (Foster City, CA)
Assignee(s): Stemcentrx, Inc. (South San Francisco, CA)
External link: USPTO website

Abstract:

Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.

0 7

Patent Number: 9,089,677

Grant date: December 31, 1969
Priority date: June 14, 2002
Estimated expiration date: June 14, 2022
Inventor(s): Soo; B. Chia (Beverly Hills, CA), Ting; Kang (Beverly Hills, CA), Wu; Ben (San Marino, CA), Zhang; Kevin (West Covina, CA)
Assignee(s): The Regents of the University of California (Oakland, CA)
External link: USPTO website

Abstract:

A transcutaneous multimodal delivery device for drug delivery and the methods of making and using the same are provided.

0 6

Patent Number: 9,089,618

Grant date: December 31, 1969
Priority date: June 14, 2002
Estimated expiration date: June 14, 2022
Inventor(s): Gold; David V. (Metuchen, NJ), Goldenberg; David M. (Mendham, NJ)
Assignee(s): Immunomedics, Inc. (Morris Plains, NJ)
External link: USPTO website

Abstract:

Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The antibodies show novel and useful diagnostic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal or benign pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. Preferably, the antibodies bind to pancreatic cancer mucins such as MUC1 or MUC5ac and are of use for the detection and diagnosis of early stage pancreatic cancer. In more preferred embodiments, the anti-pancreatic cancer antibodies can be used for immunoassay of serum samples, wherein the immunoassay detects a marker for early stage pancreatic cancer in serum. Most preferably, the serum is extracted with an organic phase, such as butanol, before immunoassay. Alternatively, immunoassay with PAM4 and anti-CA19.9 antibodies may be utilized to improve sensitivity for pancreatic cancer.